Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 650M | 3.5% |
| Gross Profit | 356M | 0.2% |
| Cost of Revenue | 500M | 3.3% |
| Operating expense | 297M | 14.6% |
| Net Income | 653M | 130.2% |
| EBITDA | 879M | 131.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 10.6B | 9.4% |
| Total Liabilities | 3.12B | 7.1% |
| Total Equity | 7.49B | 10.5% |
| Shares Outstanding | 28M | 1.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 164M | 67.6% |
| Cash from investing | -56M | 79.9% |
| Cash from financing | -96M | 0.6% |
EPS
Financial Highlights for Bio-Rad in Q3 '24
Bio-Rad reported a revenue of 650M, which is a 3.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 356M, marking a 0.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 500M, a 3.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 297M, showing a 14.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 653M, showing a 130.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 879M, showing a 131.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Bio-Rad with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
